ABSTRACT
No disponible
Subject(s)
Humans , Male , Child , Muscular Atrophy/chemically induced , Muscular Atrophy/complications , Muscular Atrophy/diagnosis , Penicillin G Benzathine/administration & dosage , Penicillin G Benzathine/adverse effects , Adrenal Cortex Hormones/therapeutic use , Drug-Related Side Effects and Adverse Reactions/complications , Drug-Related Side Effects and Adverse Reactions/drug therapy , Muscular Atrophy/drug therapy , Muscular Atrophy , Biopsy/methodsSubject(s)
Humans , Male , Middle Aged , Lichenoid Eruptions/complications , Lichenoid Eruptions/diagnosis , Lichenoid Eruptions/radiotherapy , Spectrophotometry, Ultraviolet , Ultraviolet Therapy/instrumentation , Ultraviolet Therapy/methods , Lichenoid Eruptions/physiopathology , Ultraviolet Therapy , Amyloidosis/complications , Amyloidosis/diagnosis , Amyloidosis/therapy , Hyperkeratosis, Epidermolytic/complications , Hyperkeratosis, Epidermolytic/therapySubject(s)
Amyloidosis/radiotherapy , Skin Diseases/radiotherapy , Ultraviolet Therapy , Aged , Humans , Male , Remission InductionABSTRACT
Se revisa la terapéutica disponible actualmente para el tratamiento de las micosis superficiales, las novedades existentes en el campo de la quimioterapia y los tratamientos coadyuvantes más útiles en este terreno. Se hace especial hincapié en el adecuado uso de los tratamientos convencionales y en algunos aspectos farmacoeconómicos relacionados con el tema. Se actualizan los procedimientos terapéuticos más adecuados en circunstancias especiales. Finalmente, se discuten algunas aportaciones novedosas encontradas en la literatura revisada (AU)
We review the current treatments available for superficial mycoses and discuss recent developments in pharmacotherapy and the most useful adjuvant treatments. Special emphasis is placed on the proper use of conventional therapies and a number of pharmacoeconomic issues. The review also offers an update on the best treatment choices in particular circumstances. Finally, we discuss some novel contributions found in the literature (AU)
Subject(s)
Humans , Male , Female , Mycoses/therapy , Tinea/drug therapy , Candidiasis/drug therapy , Antifungal Agents/therapeutic use , Griseofulvin/therapeutic use , Triazoles/therapeutic use , Morpholines/therapeutic use , Tinea/epidemiology , Tinea/prevention & control , Candidiasis/epidemiology , Candidiasis/prevention & control , Economics, Pharmaceutical/standards , Economics, Pharmaceutical/trends , Spain/epidemiology , Azoles/therapeutic useABSTRACT
We review the current treatments available for superficial mycoses and discuss recent developments in pharmacotherapy and the most useful adjuvant treatments. Special emphasis is placed on the proper use of conventional therapies and a number of pharmacoeconomic issues. The review also offers an update on the best treatment choices in particular circumstances. Finally, we discuss some novel contributions found in the literature.
Subject(s)
Antifungal Agents/therapeutic use , Dermatomycoses/drug therapy , Dermatomycoses/pathology , HumansABSTRACT
Scleroderma-like cutaneous changes have been reported in association with several drugs, but not with hydroxyurea (HU), to our knowledge. We report the case of a 67-year-old man who was treated with HU (hydroxycarbamide) for 12 years for a myeloproliferative disorder, and presented a progressive pruritic woody induration, symmetrically affecting both legs. He also had Gottron-like papules on the back of the metacarpophalangeal joints, and a retroauricular undifferentiated squamous cell carcinoma. On histological examination of a skin biopsy taken from the leg, massive dermal fibrosis was seen, with thickening of collagen bundles throughout the entire dermis. Six months after HU withdrawal, the skin induration resolved without scarring. Scleroderma-like syndrome has not been previously considered one of the secondary effects of HU. The evolution of our patient's condition supports a causal relationship between the HU treatment and the sclerodermiform changes of the skin.
